|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.166 SEK | -3.80% |
|
-10.86% | +26.19% |
| 05-22 | Intervacc AB Completes Successful Evaluation of Us Strain of Strangles Pathogen Ahead of Clinical Trials | CI |
| 05-15 | Sweden's Intervacc Elects New Chair | MT |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Pharmaceuticals | 8.92M | 12.35M | 8.03M | 11.79M | 20.09M | |||||
Total Assets | 329M | 265M | 260M | 187M | 294M | |||||
Interest Expense | -74K | -125K | -133K | -130K | -13K | |||||
Income Tax Expense | - | 3K | 11.39M | - | - | |||||
CAPEX | -23.21M | -6.13M | -56K | - | - | |||||
EBT | -29.38M | -64.16M | -91.46M | -75.52M | -80.82M | |||||
D&A | 6.15M | 20.86M | 30.49M | 18.53M | 18.61M | |||||
Operating Income | -29.39M | -64.41M | -93.58M | -77.28M | -83.5M | |||||
Net Income | -29.38M | -64.16M | -103M | -75.52M | -80.82M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
- Stock Market
- Stocks
- IVACC Stock
- Financials Intervacc AB
- Business Segments
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
